Given that in RA the production of ACPA antibodies is associated with a more severe clinical course, we hypothesized that differences at the immune cell level and in particular in T and B cell compartments are detectable between ACPA+ and ACPA− RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.